Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBITDA (2018 - 2025)

Historic EBITDA for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to -$23.8 million.

  • Neurogene's EBITDA fell 729.49% to -$23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.3 million, marking a year-over-year decrease of 2833.33%. This contributed to the annual value of -$82.6 million for FY2024, which is 4861.56% down from last year.
  • Per Neurogene's latest filing, its EBITDA stood at -$23.8 million for Q3 2025, which was down 729.49% from -$26.1 million recorded in Q2 2025.
  • Neurogene's EBITDA's 5-year high stood at -$12.6 million during Q2 2023, with a 5-year trough of -$26.1 million in Q2 2025.
  • Over the past 3 years, Neurogene's median EBITDA value was -$20.1 million (recorded in 2024), while the average stood at -$19.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 5984.44% in 2024, then tumbled by 729.49% in 2025.
  • Over the past 3 years, Neurogene's EBITDA (Quarter) stood at -$14.7 million in 2023, then plummeted by 46.01% to -$21.5 million in 2024, then fell by 10.63% to -$23.8 million in 2025.
  • Its last three reported values are -$23.8 million in Q3 2025, -$26.1 million for Q2 2025, and -$25.9 million during Q1 2025.